- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Guideline on glucocorticoid-induced adrenal insufficiency jointly released by European Society of Endocrinology and Endocrine Society
European Society of Endocrinology and Endocrine Society Release Joint Clinical Guideline on Glucocorticoid-induced Adrenal Insufficiency
USA: In a collaborative effort to address the complexities of glucocorticoid-induced adrenal insufficiency (GAI), the European Society of Endocrinology (ESE) and the Endocrine Society (ES) have unveiled a comprehensive clinical guideline aimed at improving the diagnosis and therapy of this condition. This joint initiative represents a significant advancement in managing a frequently encountered complication of glucocorticoid therapy.
Glucocorticoids, commonly prescribed for inflammatory and autoimmune conditions, have revolutionized the treatment of various diseases. However, their prolonged use can suppress the body's natural production of cortisol, leading to adrenal insufficiency—a condition characterized by inadequate cortisol secretion from the adrenal glands.
The joint guideline, published in The Journal of Clinical Endocrinology & Metabolism and the European Journal of Endocrinology, is designed to help clinicians manage patients who have or are at risk of developing glucocorticoid-induced adrenal insufficiency. At least 1% of the global population uses chronic glucocorticoid therapy as an anti-inflammatory or immune-suppressive agent.
This guideline is the first developed and published jointly by the Endocrine Society and the European Society of Endocrinology. The Societies are planning to publish a new joint guideline each year to maximize outreach and cover potential differences in clinical practice between Europe and the United States.
The working group behind this joint guideline was led by co-chairs Tobias Else, M.D., of the University of Michigan in Ann Arbor, Mich., and Professor Felix Beuschlein, M.D., of the University Hospital Zurich in Zurich, Switzerland.
“Our starting point was to define the clinical problem and knowledge gaps that come with glucocorticoid-induced adrenal insufficiency, for which we set out to provide some guidance – even in the absence of strong scientific evidence. We also wanted to make sure that we had good representation from Europe and the U.S. to cover potential differences in clinical practice. In this, we were privileged to gather an excellent team of specialists with great knowledge, diligence, and enthusiasm—all of which is required to get through the process of writing a guideline from scratch,” said Beuschlein.
“The discussions between the panel members during the writing of the guideline, and the review process, which included all members of both societies, has resulted in a level of consensus that has not been reached before. I hope that the global reach of this joint guideline goes beyond what either Society could reach independently.”
The key recommendations are given below:
- The researchers recommend that in general, patients on, or tapering off glucocorticoids for non-endocrine conditions do not need to be evaluated by an endocrinology specialist.
- They recommend that clinicians who implement treatment with glucocorticoids educate patients about various endocrine aspects of glucocorticoid therapy.
- It is recommended that patients on glucocorticoid therapy have access to current up-to-date, and appropriate information about different endocrine aspects of glucocorticoid therapy.
- The researchers suggest not to taper glucocorticoids in patients on short-term glucocorticoid therapy of <3-4 weeks, irrespective of the dose. In these cases, glucocorticoids can be stopped without testing due to low concern for HPA axis suppression.
- Glucocorticoid taper for patients on long-term glucocorticoid therapy should only be attempted if the underlying disease for which glucocorticoids were prescribed is controlled, and glucocorticoids are no longer required. In these cases, glucocorticoids are tapered until approaching the physiologic daily dose equivalent is achieved (eg, 4-6 mg prednisone).
- They recommend consideration of glucocorticoid withdrawal syndrome that may occur during glucocorticoid taper. When glucocorticoid withdrawal syndrome is severe, glucocorticoid dose can be temporarily increased to the most recent one that was tolerated, and the duration of glucocorticoid taper could be increased.
- They recommend against routine testing for adrenal insufficiency in patients on supraphysiologic doses of glucocorticoids, or if they are still in need of glucocorticoid treatment for the underlying disease.
- They suggest that patients taking long-acting glucocorticoids (eg, dexamethasone or betamethasone) should be switched to shorter-acting glucocorticoids (eg, hydrocortisone or prednisone) when long-acting glucocorticoids are no longer needed.
- If confirmation of recovery of the HPA axis is desired, morning serum cortisol as the first test is recommended. The value of morning serum cortisol should be considered as a continuum, with higher values more indicative of HPA axis recovery.
- They recommend that patients with current or recent glucocorticoid use who did not undergo biochemical testing to rule out glucocorticoid-induced adrenal insufficiency should receive stress dose coverage when they are exposed to stress.
- They suggest that patients aiming to discontinue glucocorticoids, but without recovery of the HPA axis in one year while on physiologic daily dose equivalent, should be evaluated by an endocrinology specialist. It is suggested that an endocrinology specialist evaluate patients on glucocorticoids and history of adrenal crisis.
- The researchers suggest that patients with current or previous glucocorticoid treatment presenting with signs and symptoms of exogenous Cushing syndrome are assumed to have glucocorticoid-induced adrenal insufficiency.
In 2025, the Societies plan to publish a joint guideline on diabetes in pregnancy; in 2026, a joint guideline on arginine vasopressin resistance and arginine vasopressin deficiency; and in 2027, a joint guideline on male hypogonadism.
Reference:
1) Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., Van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., Yedinak, C., & Dekkers, O. M. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae250
2) Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., Van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., Yedinak, C., & Dekkers, O. M. (2024). European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. European Journal of Endocrinology, 190(5), G25-G51. https://doi.org/10.1093/ejendo/lvae029
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751